Trust Signals
Written by FormBlends Medical Team. Evidence graded by study type (human RCT down to mechanism only). Last reviewed 2026-05-29. No sponsored rankings. Sources listed and linkable. Limitations stated for every peptide.Key Takeaways
- IGF-1 LR3 has the strongest direct mechanistic case for skeletal muscle hypertrophy, acting at the IGF-1 receptor (IGF-1R) to activate PI3K/Akt/mTOR, but human RCT evidence for the specific synthetic analog is absent.
- CJC-1295 (a GHRH analog) raised GH area-under-the-curve by roughly 2 to 10 fold in a published human dose-escalation trial (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism), yet no trial has measured 1-rep max or lean mass as a primary endpoint.
- BPC-157 and TB-500 contribute to strength indirectly through connective tissue and tendon repair in preclinical data; neither has human RCT strength data.
- Peptides do not match anabolic steroids for magnitude of strength gain; that comparison is made explicitly in the head-to-head table below.
- Purity is the biggest real-world variable: research-grade peptides are not GMP-manufactured, and endotoxin contamination is a documented problem in the supply chain.
What Is the Best Peptide for Strength?
IGF-1 LR3 ranks first on mechanistic grounds because it binds the IGF-1 receptor directly and drives satellite cell proliferation and mTOR-mediated protein synthesis. For GH-axis stimulation with actual human pharmacokinetic data, CJC-1295 plus Ipamorelin is the most studied stack. No peptide has a human RCT proving strength gains. Choose based on evidence type, not marketing copy.Table of Contents
- Evidence Ledger: All Major Claims Graded
- How Strength Peptides Work: Mechanism With Numbers
- The 5 Best Peptides for Strength, Ranked
- What Most Pages Get Wrong
- Why the Storage and Stability Rules Exist: The Chemistry
- Honest Head-to-Head: Peptides vs. Real Alternatives
- Label and COA Literacy: How to Judge a Product
- Dosing Reference Table
- FAQ
- Sources
Evidence Ledger: All Major Claims Graded
Every major claim on this page is graded below. Confidence ratings follow approximate GRADE conventions: High means consistent human RCT evidence; Moderate means human data with limitations; Low means animal or small human pilot data; Very Low means mechanism or cell-only data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| CJC-1295 raises GH and IGF-1 blood levels in humans | Human dose-escalation trial (Teichman et al., 2006, n=21) | Positive (dose-dependent GH increase) | Moderate |
| Ipamorelin produces selective GH pulse with less cortisol than GHRP-6 | Animal study (Raun et al., 1998) plus mechanistic comparison | Positive (selectivity) | Low |
| IGF-1 LR3 activates IGF-1R and stimulates muscle protein synthesis | Cell culture and animal studies; endogenous IGF-1 human RCTs | Positive (in vitro, animal) | Low (for the synthetic analog specifically) |
| BPC-157 accelerates tendon and muscle healing in rodents | Multiple rat studies (Pevec et al., 2010; Sikiric group publications) | Positive (preclinical) | Low |
| TB-500 (Thymosin beta-4 fragment) promotes actin polymerization and tissue repair | Animal and in vitro studies | Positive (preclinical) | Very Low for human strength |
| Follistatin 344 suppresses myostatin and increases muscle mass | Animal gene-therapy and in vitro; no human RCT for injected peptide | Positive (animal gene therapy) | Very Low for injected human use |
| Any peptide produces strength gains comparable to anabolic steroids | No trial evidence; indirect comparison only | Negative (peptides lose this comparison) | High (steroids are superior on magnitude) |
How Strength Peptides Work: Mechanism With Numbers
Strength gains at the cellular level require three things: net positive muscle protein balance (synthesis exceeds breakdown), satellite cell activation for hypertrophy, and connective tissue integrity to handle progressive load. Peptides target these pathways through two primary axes.
The GH/IGF-1 Axis
Growth hormone releasing hormone (GHRH) analogs like CJC-1295 bind the GHRH receptor on pituitary somatotrophs, increasing pulsatile GH secretion. GH then stimulates hepatic and local IGF-1 production. IGF-1 binds IGF-1R, a receptor tyrosine kinase, triggering autophosphorylation and downstream activation of PI3K, then Akt, then mTORC1. mTORC1 phosphorylates S6K1 and 4E-BP1, two proteins that control ribosomal biogenesis and cap-dependent translation. This pathway is the molecular basis of muscle protein synthesis. The relevant figure: endogenous IGF-1 infusion studies show measurable increases in muscle protein synthesis rates in healthy adults (Fryburg et al., 1995, Journal of Clinical Investigation). Whether a subcutaneous GH-releasing peptide achieves the same downstream IGF-1 tissue concentration as direct infusion is not established.
Ghrelin-Axis Peptides (GHRPs)
Ipamorelin mimics ghrelin at the GHS-R1a receptor (growth hormone secretagogue receptor), releasing a GH pulse. Raun et al. (1998) reported that Ipamorelin at 125 mcg/kg in rats produced GH peaks comparable to GHRP-6 but without the ACTH/cortisol elevation seen with GHRP-6. Cortisol is catabolic to muscle; blunting it theoretically preserves the anabolic window. What this mechanism does NOT prove: that the GH pulse from Ipamorelin translates to meaningful strength improvement in trained humans on top of a solid resistance training program.
IGF-1 LR3 Specifically
IGF-1 LR3 (long arginine-3 IGF-1) is a synthetic analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF-binding proteins (IGFBPs) by roughly 2 to 3 orders of magnitude compared to native IGF-1, according to cell-binding studies, extending the free half-life from minutes (native IGF-1) to several hours in circulation. The result is more sustained IGF-1R occupancy. This is a pharmacokinetic advantage established in vitro. What it does not prove: that injected IGF-1 LR3 in a healthy, euglycemic adult (who already has physiological IGF-1) produces additive hypertrophy beyond the ceiling of normal GH/IGF-1 signaling.
Repair Peptides (BPC-157, TB-500)
BPC-157 is a 15-amino-acid partial sequence of a gastric peptide. Rat studies by Sikiric and colleagues show upregulation of growth factor receptors (including VEGFR2) and accelerated tendon-to-bone healing. TB-500 is a synthetic fragment of Thymosin beta-4 corresponding roughly to the actin-binding domain; it promotes actin polymerization in damaged tissue. Neither pathway directly stimulates myofibrillar protein synthesis. Their strength relevance is training continuity: if you recover faster from connective tissue microtrauma, you train harder and more frequently.
The 5 Best Peptides for Strength, Ranked
1. IGF-1 LR3
Mechanism: direct IGF-1R agonist, reduced IGFBP binding, extended free half-life. Ranked first because it acts at the terminal effector of the GH axis rather than upstream. Caveat: no human RCT for the LR3 analog specifically. Risk: hypoglycemia (IGF-1R activation lowers blood glucose), and theoretical promotion of pre-existing neoplasms with sustained use.
2. CJC-1295 plus Ipamorelin
The most used research peptide stack with the closest thing to human pharmacokinetic validation. CJC-1295 (with DAC, drug affinity complex) extends GH pulse duration; Ipamorelin provides the acute GH release with a cleaner hormonal profile. Teichman et al. (2006) showed dose-dependent GH and IGF-1 increases in healthy adults. Used together, the combination targets both the amplitude and duration of GH pulsatility. No published trial reports strength as an outcome.
3. BPC-157
Ranked third not because it builds strength directly but because connective tissue resilience is a rate-limiting factor in serious strength training. Rodent data on Achilles tendon repair (Pevec et al., 2010) is among the more methodologically sound in this category. Routes studied include subcutaneous and oral (oral bioavailability in rats appears meaningful, though human oral bioavailability is unconfirmed). No human RCT exists.
4. TB-500 (Thymosin beta-4 fragment Ac-LKKTETQ)
Actin-sequestering peptide with regenerative properties in cardiac and skeletal muscle animal models. Longer half-life than BPC-157 in preclinical data. WADA-prohibited. Evidence base is weaker than BPC-157 for musculoskeletal applications specifically. Rationale for inclusion: training volume sustainability through soft-tissue recovery.
5. Follistatin 344
Ranked fifth because the mechanism (myostatin inhibition) is genuinely relevant to muscle mass, but the human evidence for injected Follistatin 344 peptide is essentially absent. Lee and McPherron's knockout mouse work established myostatin's role in limiting muscle mass convincingly. The gap between mouse genetics and human subcutaneous peptide injection is enormous. Listed here for completeness with a very-low confidence rating.
What Most Pages Get Wrong
This is the section commodity pages skip.
Bioavailability after subcutaneous injection is not 100%. Most peptide pages treat a 100 mcg subcutaneous injection as delivering 100 mcg to target tissue. Subcutaneous bioavailability for peptides varies by molecular size, sequence, and injection site vascularity. For larger peptides (above roughly 1500 Da molecular weight), lymphatic rather than capillary uptake dominates, slowing the time-to-peak and reducing effective plasma concentration compared to intravenous dosing. IGF-1 LR3 (MW approximately 9,117 Da) is large enough that subcutaneous bioavailability in humans is meaningfully lower than IV, though exact figures for the LR3 analog specifically have not been published in peer-reviewed human studies.
The GH pulse timing matters more than most users realize. GH-releasing peptides should ideally be dosed in a fasted, low-glucose state because elevated glucose blunts somatotroph responsiveness via somatostatin. Users who inject CJC-1295 and Ipamorelin immediately post-workout with a carbohydrate drink are blunting a portion of the GH response. This is not speculation; it follows from established hypothalamic-pituitary glucose sensing physiology.
Research-grade purity claims are unverifiable without an independent COA. A certificate of analysis showing 98% purity means nothing if it came from the same lab that produced the peptide. Independent third-party HPLC plus mass spec confirmation is the minimum credibility standard. A significant proportion of research peptides tested by independent labs in published reviews have shown incorrect molecular weight, lower-than-claimed purity, or endotoxin contamination. Endotoxin triggers inflammatory responses that are directly counterproductive to recovery and adaptation.
Stacking peptides is not additive in a simple way. Combining a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) is synergistic because they work on different receptor populations. But adding IGF-1 LR3 on top of a GHRH/GHRP stack theoretically risks sustained IGF-1R saturation and downstream feedback that suppresses endogenous GH pulsatility. The long-term endocrine consequences of this are not studied in humans.
Why the Storage Rules Exist: The Chemistry
Peptides are chains of amino acids linked by peptide bonds. Those bonds are susceptible to two main degradation pathways at ambient conditions.
Hydrolysis: In solution, water attacks the carbonyl carbon of a peptide bond. The rate is accelerated by heat and extremes of pH. This is why lyophilized powder is stable for months at refrigerator temperature, but reconstituted peptide solution degrades over days to weeks at room temperature. Bacteriostatic water (containing 0.9% benzyl alcohol) slows microbial growth but does not stop hydrolysis. Once reconstituted, peptides should stay at 2 to 8 degrees Celsius and be used within roughly 28 to 30 days. The benzyl alcohol preservative is the reason bacteriostatic water is chosen over sterile water for multi-dose vials; it is not a peptide stabilizer but a microbial inhibitor.
Oxidation: Methionine and cysteine residues are particularly vulnerable to oxidative degradation. Light exposure catalyzes free radical reactions that attack these side chains. This is why amber or opaque vials are used and why storing peptides next to a window or under fluorescent lighting accelerates potency loss. The practical rule: amber glass, refrigerated, away from light, used within the reconstitution window.
Freeze-thaw degradation: Repeated cycling between frozen and thawed states physically stresses peptide secondary structure and creates ice crystal damage at the protein level. For vials that will be used over weeks, aliquoting into single-use portions before freezing and thawing only the day's dose is the correct approach.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Comparison | Peptides (GH axis stack) | Alternative | Winner on Strength Magnitude | Winner on Safety Profile |
|---|---|---|---|---|
| vs. Anabolic Steroids (testosterone) | Modest, indirect GH/IGF-1 elevation; weeks to see effect | Direct androgen receptor agonism; large, fast strength/mass gains | Steroids (not close) | Peptides (short-term data) |
| vs. Creatine Monohydrate | Unproven strength benefit in human RCT | Multiple meta-analyses confirm 5 to 8% strength increase over placebo | Creatine (evidence quality wins) | Roughly equivalent (creatine well-tolerated) |
| vs. Recombinant HGH (rhGH) | Stimulates endogenous GH; more physiological pulsatility | Supraphysiological exogenous GH; suppresses endogenous production | rhGH (higher absolute GH levels) | Peptides (preserve endogenous axis) |
| vs. Progressive Overload Alone | No additive benefit proven in trained humans | Primary driver of all strength adaptation | Training (foundational) | Training (no risk) |
| BPC-157 vs. NSAIDs for connective tissue recovery | Possibly promotes healing in preclinical models | NSAIDs reduce pain but may impair tendon healing with chronic use | Unclear (no human RCT for either in this context) | BPC-157 (preclinical data suggests healing vs. inhibition) |
Label and COA Literacy: How to Judge a Product
This is the most practically useful section for someone about to spend money.
What a legitimate COA must include: HPLC purity percentage with the analytical method and column type stated (target above 98% for research grade). Mass spectrometry (ESI-MS or MALDI) confirming the molecular weight matches the theoretical weight of the correct sequence. LAL (limulus amebocyte lysate) endotoxin test result (acceptable threshold is typically below 1 EU/mg for research peptides, though pharmaceutical standards are stricter). Residual solvent testing if relevant. The testing laboratory name and date.
Red flags on a COA: Purity stated as a single number with no method. No mass spec. COA dated more than 12 months ago. The issuing lab shares a name or address with the supplier. No endotoxin data.
Reading the vial label: The stated amount (e.g., 5 mg) is total lyophilized peptide in the vial, not concentration. Concentration is determined by how much reconstitution solvent you add. Standard practice is 1 to 2 mL of bacteriostatic water per vial, giving a concentration you calculate yourself. Example: 5 mg peptide in 2 mL bacteriostatic water equals 2,500 mcg per mL (2.5 mg/mL). A 100 mcg dose from this preparation requires 0.04 mL (40 microliters) on an insulin syringe. Verify your syringe calibration before use.
What a degraded peptide looks like: Visible particulates in a reconstituted solution that was previously clear. Discoloration (yellowing). Unusual odor. Loss of expected potency over time without any change in storage conditions. None of these are guaranteed signs, since a peptide can degrade at the molecular level without visible change. This is why storage discipline matters from day one, not after you notice a problem.
Dosing Reference Table (Research Protocols, Not Clinical Recommendations)
| Peptide | Form | Research Dose Range Reported | Frequency in Protocols | Half-life Estimate |
|---|---|---|---|---|
| CJC-1295 with DAC | Lyophilized, SubQ | 1 to 2 mg per week | Once or twice weekly | Approximately 6 to 8 days (with DAC) |
| Ipamorelin | Lyophilized, SubQ | 100 to 300 mcg per injection | 2 to 3 times daily (fasted) | Approximately 2 hours |
| IGF-1 LR3 | Lyophilized, SubQ or IM | 20 to 60 mcg per day (community reports) | Once daily post-workout | Approximately 20 to 30 hours (reduced IGFBP binding) |
| BPC-157 | Lyophilized, SubQ | 250 to 500 mcg per day (animal-translated) | Once or twice daily | Short (minutes to low hours in plasma) |
| TB-500 | Lyophilized, SubQ | 2 to 5 mg per week (community reports) | Once or twice weekly | Not well characterized in humans |
| Follistatin 344 | Lyophilized, SubQ | No established human dose | N/A | Very short; not established |
FAQ
What is the best peptide for strength overall?
IGF-1 LR3 has the strongest direct mechanistic case for muscle hypertrophy and strength via IGF-1R activation and satellite cell proliferation. However, human RCT evidence for the synthetic peptide form is limited, and real-world results depend heavily on purity and dosing context. CJC-1295 plus Ipamorelin is the more commonly studied GHRH/ghrelin-axis stack with moderate human pharmacokinetic data.
Does CJC-1295 actually increase strength in humans?
CJC-1295 alone raises GH and IGF-1 blood levels in human trials (Teichman et al., 2006), but no peer-reviewed RCT has measured strength outcomes like 1-rep max or lean mass as primary endpoints for this peptide specifically. The GH elevation is real; the strength translation is inferred.
Is BPC-157 useful for strength or just recovery?
BPC-157 evidence is largely preclinical (rat models of tendon and muscle repair). It does not have direct anabolic or strength-building data in humans. Its value in a strength context is indirect: faster recovery from training-related tissue damage, not direct muscle protein synthesis stimulation.
What dose of IGF-1 LR3 is used in research?
Research protocols have used doses in the range of 20 to 120 mcg per day in cell and animal studies. Human experimentation exists in bodybuilding communities at roughly 20 to 60 mcg per day, but no peer-reviewed human RCT has established a safe or effective dose for the synthetic long-arginine-3 variant specifically.
How does Ipamorelin compare to GHRP-6 for strength?
Ipamorelin produces a cleaner GH pulse with minimal cortisol or prolactin elevation compared to GHRP-6. GHRP-6 drives stronger acute GH release but also raises cortisol and causes significant hunger. For a strength-focused protocol, Ipamorelin paired with CJC-1295 is generally preferred because the cortisol blunting preserves the anabolic environment.
Are strength peptides legal to use?
In the US, most research peptides are not FDA-approved drugs and are sold for research purposes only, making human self-administration a legal gray area. WADA prohibits GH-releasing peptides (GHRPs and GHRHs) in competitive sport. IGF-1 and its analogs are also explicitly WADA-prohibited. Check current WADA and national anti-doping lists before competing.
What should a COA for a strength peptide show?
A legitimate COA should include HPLC purity (target above 98%), mass spectrometry confirmation of molecular weight, absence of bacterial endotoxins (LAL test), and residual solvent testing. Avoid suppliers who only show a single purity percentage with no analytical method listed.
Can peptides replace steroids for strength gains?
No. Anabolic steroids bind androgen receptors directly and produce substantially larger, faster strength and mass gains than any peptide studied to date. Peptides work upstream (stimulating GH/IGF-1 axis or aiding recovery) and produce comparatively modest effects. Head-to-head, peptides lose on magnitude but have a more favorable short-term safety profile in available data.
How should CJC-1295 with Ipamorelin be stored?
Lyophilized powder should be stored at 2 to 8 degrees Celsius and shielded from light. After reconstitution with bacteriostatic water, use within 28 to 30 days and keep refrigerated. Repeated freeze-thaw cycles degrade peptide bonds; aliquot if you plan to use the vial over weeks.
What is Follistatin 344 and does it build strength?
Follistatin 344 is a myostatin-inhibiting protein fragment. Animal gene-therapy data shows dramatic muscle growth when myostatin is suppressed. However, no human RCT exists for injected Follistatin 344 peptide. The circulating half-life is short, and whether subcutaneous dosing achieves meaningful myostatin inhibition in humans is unproven. Evidence is very low.
What is the biggest risk with peptide use for strength?
The biggest practical risk is product impurity: research-grade peptides are not manufactured under pharmaceutical GMP and may contain bacterial endotoxins, wrong sequences, or truncated fragments. Beyond purity, GH-axis stimulation carries risks of insulin resistance, fluid retention, and potential promotion of pre-existing neoplasms with long-term use.
Sources
- Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism, 2006; 91(3):799-805.
- Raun K et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998; 139(5):552-561.
- Fryburg DA et al. "Insulin-like growth factor I exerts growth hormone and insulin-like actions on human muscle protein metabolism." American Journal of Physiology, 1995; 268(2 Pt 1):E331-40.
- Pevec D et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor, 2010; 16(3):BR81-88.
- Sikiric P et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD)." Current Pharmaceutical Design, 2011; 17(16):1612-32.
- Lee SJ, McPherron AC. "Regulation of myostatin activity and muscle growth." Proceedings of the National Academy of Sciences, 2001; 98(16):9306-11.
- Goldspink G. "Mechanical signals, IGF-I gene splicing, and muscle adaptation." Physiology (Bethesda), 2005; 20:232-238.
- Malm C et al. "Supplementation with ubiquinone-10 causes cellular
Related peptide guides